Kidney and Drugs / Nephrotoxicity

📋 Key Information Summary

📋

Drug-induced nephrotoxicity accounts for approximately 20% of community- and hospital-acquired acute kidney injury (AKI) in Australia.
NSAIDs cause nephrotoxicity primarily through haemodynamic mechanisms — inhibition of renal prostaglandin synthesis reduces afferent arteriolar vasodilation, precipitating pre-renal AKI.
COX-2 inhibitors (celecoxib, etoricoxib) are not renal-sparing; they carry equivalent nephrotoxic risk to traditional NSAIDs.
Aminoglycosides (gentamicin, tobramycin) cause dose-dependent proximal tubular necrosis (acute tubular necrosis — ATN); trough levels must be monitored and nephrotoxic courses minimised.
Cisplatin causes direct tubular toxicity with cumulative dose-dependent AKI; aggressive IV hydration with 0.9% sodium chloride is mandatory pre- and post-infusion.
Lithium accumulates in the distal collecting duct, causing nephrogenic diabetes insipidus (NDI) acutely and chronic tubulointerstitial nephritis with chronic use; eGFR must be monitored 6-monthly.
All renally excreted or nephrotoxic drugs require dose adjustment based on eGFR (CKD-EPI 2021 equation); calculate using the patient's most recent serum creatinine.
Risks of nephrotoxicity are multiplicative — concurrent use of two or more nephrotoxins (e.g., NSAID + ACE inhibitor + diuretic — the "triple whammy") dramatically increases AKI risk.
For Aboriginal and Torres Strait Islander peoples, CKD prevalence is 2–3 times higher; drug dosing must account for reduced renal reserve and remote monitoring limitations.
Use the CKD-EPI 2021 creatinine equation (without race coefficient) to estimate GFR for all drug dose adjustments in Australia.
Prescribing in CKD requires checking a medicines resource (e.g., Australian Medicines Handbook, renal drug databases) for every new and existing medication.
Refer for nephrology input when eGFR <30 mL/min/1.73 m², when nephrotoxic drug cessation does not improve AKI within 48–72 hours, or for complex polypharmacy in advanced CKD.

Introduction & Australian Epidemiology

Drug-induced nephrotoxicity remains one of the most common preventable causes of acute kidney injury (AKI) in Australia, accounting for an estimated 20% of all AKI presentations in hospital and a significant proportion in the community. The kidney is uniquely vulnerable to drug toxicity because of its high blood flow (20–25% of cardiac output), concentration of drugs in the medullary interstitium, and metabolic activity of tubular epithelial cells.

The mechanisms by which drugs injure the kidney are diverse and include haemodynamic alterations (e.g., NSAIDs, ACE inhibitors), direct tubular cell toxicity (e.g., aminoglycosides, cisplatin, amphotericin B), crystal nephropathy (e.g., aciclovir, methotrexate, indinavir), thrombotic microangiopathy (e.g., gemcitabine, VEGF inhibitors), and immune-mediated tubulointerstitial nephritis (e.g., proton pump inhibitors, penicillins, NSAIDs).

In Australia, approximately 1.7 million adults have chronic kidney disease (CKD), with stages 3–5 affecting over 600,000 people. The burden is disproportionately borne by Aboriginal and Torres Strait Islander peoples, among whom CKD prevalence is 2–3 times that of non-Indigenous Australians. Polypharmacy is common in CKD populations — up to 80% of patients with eGFR <60 mL/min/1.73 m² take five or more regular medications, amplifying nephrotoxic risk.

The concept of the "triple whammy" — concurrent use of an NSAID (or COX-2 inhibitor), an ACE inhibitor or angiotensin receptor blocker (ARB), and a diuretic — is well recognised in Australian prescribing safety literature as a major risk factor for AKI, particularly in elderly patients during intercurrent illness or dehydration.

This guideline provides an Australian-focused overview of the major drug classes causing nephrotoxicity, with practical recommendations for prevention, monitoring, and dose adjustment in renal impairment.

NSAIDs & COX-2 Inhibitors (Haemodynamic Nephrotoxicity)

Mechanism

Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase (COX) enzymes, reducing renal prostaglandin E₂ (PGE₂) and prostacyclin (PGI₂) synthesis. These prostaglandins normally mediate afferent arteriolar vasodilation to maintain glomerular filtration rate (GFR), particularly in states of reduced renal perfusion (hypovolaemia, heart failure, cirrhosis, CKD). Their inhibition causes afferent arteriolar vasoconstriction, reducing GFR and precipitating pre-renal AKI.

With prolonged use, NSAIDs can also cause sodium and water retention (oedema, hypertension), hyperkalaemia (via suppression of renin–aldosterone), and — less commonly — acute interstitial nephritis (AIN) or papillary necrosis.

⚠️

Triple whammy warning: Concurrent use of an NSAID (or COX-2 inhibitor), an ACE inhibitor or ARB, and a diuretic carries a 30-fold increased risk of AKI compared with use of an ACE inhibitor/ARB alone. This combination should be avoided, particularly in elderly patients and those with reduced oral fluid intake (NPS MedicineWise, 2022).

COX-2 Selective Inhibitors

COX-2 inhibitors (celecoxib, etoricoxib) were initially thought to be renal-sparing because COX-1–derived prostaglandins play the predominant role in renal haemostasis. However, COX-2 is constitutively expressed in the macula densa, thick ascending limb, and medullary interstitial cells. Clinical evidence confirms that COX-2 inhibitors carry equivalent risk of haemodynamic nephrotoxicity, sodium retention, and hyperkalaemia as non-selective NSAIDs.

Risk Factors for NSAID Nephrotoxicity

Risk Factor	Rationale
eGFR <60 mL/min/1.73 m²	Reduced renal reserve; prostaglandin-dependent GFR maintenance
Age ≥65 years	Age-related GFR decline, polypharmacy, reduced thirst mechanism
Concurrent ACEi/ARB + diuretic	"Triple whammy" — synergistic haemodynamic insult
Heart failure (NYHA III–IV)	Low cardiac output → prostaglandin-dependent renal perfusion
Cirrhosis / hepatic impairment	Splanchnic vasodilation → renal vasoconstriction compensated by PGs
Dehydration / diarrhoea / vomiting	Reduced effective circulating volume
Concurrent nephrotoxins (aminoglycosides, contrast)	Additive renal injury
Duration >7 days	Cumulative exposure increases risk of AIN and CKD progression

Management

Prevention: Avoid NSAIDs where possible in patients with eGFR <30 mL/min/1.73 m² (relative contraindication). Use for shortest possible duration at lowest effective dose.
When NSAID is necessary in CKD 3 (eGFR 30–59): Use with caution, monitor serum creatinine and potassium at baseline, 1–2 weeks after initiation, and periodically thereafter.
If AKI develops: Cease the NSAID immediately. Most haemodynamic AKI is reversible within 3–7 days of cessation. Provide IV 0.9% sodium chloride if dehydrated.
Alternatives for analgesia: Paracetamol (first-line), tramadol (dose-adjust in CKD), low-dose opioid (with renal caution), topical NSAIDs (lower systemic exposure).

💊

Ibuprofen

Nurofen® · Generic · NSAID (non-selective)

Adult dose 200–400 mg PO TDS–QID with food; max 1200 mg/day OTC, 2400 mg/day prescription

Renal adjustment Avoid if eGFR <30; use with caution eGFR 30–59; monitor creatinine/K⁺

PBS status ✔ PBS General Benefit

💊

Celecoxib

Celebrex® · COX-2 selective inhibitor

Adult dose 100–200 mg PO BD; max 400 mg/day (osteoarthritis); 200 mg BD (RA)

Renal adjustment Not renally cleared, but avoid eGFR <30; haemodynamic risk persists; halve dose eGFR 30–59

PBS status ⚠ PBS Authority Required

Aminoglycosides & Cisplatin (Tubular Toxicity)

Aminoglycosides

Aminoglycosides (gentamicin, tobramycin, amikacin) are concentration-dependent bactericidal antibiotics widely used in Australia for Gram-negative sepsis, endocarditis (synergistic), and perioperative prophylaxis. They are freely filtered at the glomerulus and actively reabsorbed by proximal tubular epithelial cells via megalin-mediated endocytosis, where they accumulate in lysosomes and cause direct tubular cell injury, necrosis, and apoptosis.

🚨

Critical safety point: Aminoglycoside nephrotoxicity is dose- and duration-dependent. Courses should be limited to the shortest effective duration (ideally ≤5 days for empiric therapy). Once-daily dosing (extended-interval) is preferred as it is at least as effective and less nephrotoxic than multiple daily dosing (eTG Antibiotic 2024).

Dosing Strategy in Australia

Once-daily dosing (ODD): Gentamicin 5–7 mg/kg IV (based on ideal or adjusted body weight) once daily. Preferred for most indications. Trough level taken just before the next dose; target trough <1 mg/L (ideally <0.5 mg/L for courses >5 days).
Extended-interval dosing in CKD: If eGFR <40 mL/min/1.73 m², extended-interval dosing may be unreliable. Consult infectious diseases or pharmacy for individualised dosing and monitoring.
Monitoring: Serum creatinine and potassium daily during treatment. Trough level at 48 hours and then every 2–3 days. Discontinue if trough ≥2 mg/L or creatinine rises >50% from baseline.
Duration: Maximum 5–7 days for empiric therapy. Longer courses (e.g., endocarditis synergistic therapy) require enhanced monitoring and nephrology input.

Cisplatin

Cisplatin is a platinum-based chemotherapeutic agent used in testicular, ovarian, bladder, head and neck, and lung cancers. It is freely filtered at the glomerulus and actively taken up by proximal tubular cells via organic cation transporter 2 (OCT2), where it forms DNA crosslinks and generates reactive oxygen species, causing tubular necrosis and apoptosis. Nephrotoxicity is the principal dose-limiting toxicity.

Prevention of Cisplatin Nephrotoxicity

1

Pre-hydration

1–2 L of 0.9% sodium chloride IV over 2–4 hours pre-infusion. Maintain adequate urine output (>100 mL/hr).

2

Mannitol diuresis (if used)

Mannitol 20% IV 12.5–25 g may be added to promote diuresis; evidence is mixed but used in some Australian protocols.

3

Post-hydration

1.5–2 L 0.9% NaCl IV over 4–6 hours post-cisplatin. Additional oral fluids encouraged for 24–48 hours.

4

Electrolyte replacement

Monitor and replace magnesium, potassium, and phosphate. Hypomagnesaemia is extremely common (up to 90% of patients).

5

Dose modification

Hold cisplatin if eGFR <60 or creatinine rises >25% from baseline. Consider carboplatin substitution (Calvert formula dosing).

Renal Thresholds for Aminoglycoside & Cisplatin Use

Drug	eGFR Threshold	Action
Gentamicin (ODD)	eGFR <40	Extended-interval unreliable; consider ID/pharmacy dosing; daily levels
Gentamicin	eGFR <20	Avoid if possible; use alternative agent
Tobramycin	eGFR <40	As per gentamicin — individualise dose
Cisplatin	eGFR <60	Contraindicated in most protocols; switch to carboplatin
Cisplatin	eGFR <45	Absolute contraindication for full-dose cisplatin

Lithium Nephrotoxicity

Mechanisms

Lithium has a narrow therapeutic index (0.4–1.0 mmol/L) and is exclusively renally excreted with no hepatic metabolism. It is freely filtered at the glomerulus and approximately 80% is reabsorbed in the proximal tubule. Lithium accumulates in principal cells of the collecting duct, where it inhibits glycogen synthase kinase 3β (GSK-3β), downregulates aquaporin-2 (AQP2) channels, and impairs the renal response to antidiuretic hormone (ADH), leading to nephrogenic diabetes insipidus (NDI).

Chronic lithium exposure (>10 years) causes chronic tubulointerstitial nephritis, progressive CKD (estimated 15–20% of long-term lithium users develop eGFR <60), and — rarely — renal tubular acidosis (type 1 or 2) or hyperparathyroidism-mediated hypercalcaemia.

⚠️

Lithium toxicity precipitants: Any cause of reduced GFR (dehydration, NSAIDs, ACEi/ARB, diarrhoea, vomiting) can precipitate lithium toxicity by reducing renal lithium clearance. Concurrent use of NSAIDs with lithium is a particularly hazardous combination — NSAIDs reduce renal lithium clearance by 15–25%. Thiazide diuretics are another major precipitant (reduce proximal tubule lithium reabsorption paradoxically via volume contraction).

Monitoring Requirements

Parameter	Frequency	Action Threshold
Serum lithium level	Every 3–6 months (stable); within 5–7 days of dose change	Target 0.4–0.8 mmol/L (maintenance); toxicity >1.2 mmol/L
eGFR / serum creatinine	Every 6 months	If eGFR decline >5 mL/min/year — nephrology referral
Electrolytes (Na⁺, K⁺)	Every 6 months	Hyperkalaemia, hyponatraemia
Calcium / PTH	Annually	Hypercalcaemia (lithium-associated hyperparathyroidism in 10–25%)
Thyroid function (TSH)	Every 6 months	Hypothyroidism in 5–35%
Urine osmolality (water deprivation test)	If polyuria (>3 L/day)	NDI: urine osmolality <300 mOsm/kg after 8-hr fluid restriction

Management of Lithium-Induced Nephrotoxicity

Acute toxicity: Cease lithium. IV 0.9% NaCl for rehydration. Monitor lithium levels 4–6 hourly. Consider haemodialysis if lithium >4 mmol/L (acute ingestion), >2.5 mmol/L (chronic), or if symptomatic (seizures, reduced consciousness, cardiac arrhythmia) regardless of level.
Chronic CKD: The decision to continue or cease lithium in CKD is complex and requires shared decision-making involving psychiatry, nephrology, and the patient. Many patients can continue lithium with eGFR 30–59 if psychiatrically stable and lithium is essential, with enhanced renal monitoring.
NDI management: Amiloride 5–10 mg PO daily blocks lithium entry into principal cells via ENaC and may partially reverse NDI. Adequate free water intake essential.
Alternative mood stabilisers (if lithium must be ceased): Sodium valproate, lamotrigine, or carbamazepine — discuss with psychiatry.

💊

Lithium carbonate

Lithicarb® · Priadel® · Quilonum®

Adult dose 250–500 mg PO BD–TDS; titrate to serum level 0.4–0.8 mmol/L

Renal adjustment eGFR 30–59: reduce dose 50%, monitor levels more frequently; eGFR <30: avoid or use with extreme caution under specialist supervision

PBS status ✔ PBS General Benefit

Drug Dosing in Renal Impairment

Accurate estimation of renal function is essential for safe prescribing in CKD. The CKD-EPI 2021 creatinine equation (without race coefficient) is recommended in Australia for eGFR reporting and drug dose adjustment. The Cockcroft-Gault equation estimates creatinine clearance (CrCl) and is still used for some drug-specific dosing recommendations in product information.

CKD Staging and Prescribing Implications

CKD 1–2

eGFR ≥60 mL/min/1.73 m²

Most drugs require no dose adjustment. Monitor renal function annually. Avoid unnecessary nephrotoxins.

Setting: GP / community prescribing

CKD 3a–3b

eGFR 30–59 mL/min/1.73 m²

Many drugs require dose reduction or extended dosing intervals. Check every new prescription. Monitor eGFR 3–6 monthly.

Setting: GP with specialist co-management

CKD 4–5

eGFR <30 mL/min/1.73 m²

Majority of renally cleared drugs require significant dose adjustment. Avoid nephrotoxins. Nephrology involvement essential. Dialysis planning if eGFR <15.

Setting: Nephrologist-led + GP shared care

Common Drugs Requiring Dose Adjustment in CKD

Drug	Normal Dose	eGFR 30–59	eGFR 10–29	eGFR <10 / Dialysis
Metformin	500–1000 mg BD	Max 1000 mg/day; review at eGFR 30	Cease (eGFR <30)	Contraindicated
Enoxaparin	1 mg/kg BD or 1.5 mg/kg OD	1 mg/kg OD (prophylaxis: 20 mg OD)	1 mg/kg OD; consider anti-Xa monitoring	Use UFH instead; not dialysable
Gabapentin	300–1200 mg TDS	200–700 mg BD	200–700 mg OD	100–300 mg OD; supplement post-HD
Pregabalin	75–300 mg BD	75–300 mg/day in divided doses	25–150 mg/day	25–75 mg/day; supplement post-HD
Morphine	10–20 mg PO 4-hourly	Reduce dose; active metabolite (M6G) accumulates	Avoid; use fentanyl or buprenorphine	Contraindicated — M6G toxicity risk
Vancomycin	15–20 mg/kg IV 8–12 hourly	15 mg/kg IV 12–24 hourly; AUC-guided dosing	15 mg/kg IV 24–48 hourly; trough monitoring	15 mg/kg IV 48–96 hourly; dialysis-adjusted
Allopurinol	100–300 mg PO daily	100–200 mg daily	100 mg daily or alternate days	100 mg 2–3 times/week post-dialysis
Colchicine	500 μg BD–TDS (acute gout)	500 μg BD; max 1 mg/day	500 μg OD; avoid repeated courses	Contraindicated (cumulative toxicity)

ℹ️

Australian resources for renal drug dosing: The Australian Medicines Handbook (AMH) includes a renal impairment dosing section for all PBS-listed drugs. The Kidney Health Australia "Caring for Australasians with Renal Impairment" (CARING) guidelines and individual state renal drug databases (e.g., NSW Therapeutic Advisory Group Renal Drug Database) provide additional guidance.

Principles of Dose Adjustment

Reduce the dose when the drug has active/toxic metabolites that accumulate in renal impairment (e.g., morphine, codeine, dabigatran).
Extend the dosing interval when the parent drug accumulates but is non-toxic at standard peak concentrations (e.g., aminoglycosides, vancomycin).
Use a loading dose (unchanged from normal renal function) when therapeutic levels need to be achieved quickly (e.g., digoxin, phenytoin), then reduce the maintenance dose.
Monitor drug levels where available (vancomycin, gentamicin, lithium, digoxin, phenytoin) and adjust based on measured concentrations.
Consider dialysis clearance: Some drugs are removed by haemodialysis (e.g., lithium, gabapentin, vancomycin) and require post-dialysis supplementation. Others are not dialysable (e.g., digoxin, aminoglycosides with tissue accumulation).

Drugs to Avoid in CKD

🚨

NSAIDs: Avoid if eGFR <30; extreme caution eGFR 30–59.
Metformin: Cease if eGFR <30 (lactic acidosis risk). Reduce dose eGFR 30–45.
Nitrofurantoin: Ineffective and toxic if eGFR <45 (poor urinary concentration; peripheral neuropathy risk).
Methenamine (hiprex): Ineffective if eGFR <30 (requires acidic urine; inadequate urinary concentration).
Gadolinium-based contrast agents: Risk of nephrogenic systemic fibrosis if eGFR <30; use group II agents only (e.g., gadoterate, gadobutrol).
Dabigatran: Contraindicated if eGFR <30 (significant accumulation; no reversal agent readily available in all centres).
Spironolactone / eplerenone: Avoid if eGFR <30 or K⁺ >5.0 mmol/L (hyperkalaemia risk).
Trimethoprim: Increases serum creatinine (inhibits tubular secretion — not true AKI) and can cause hyperkalaemia; use with caution in CKD.

Pathophysiology of Drug-Induced Kidney Injury

Understanding the mechanism of drug nephrotoxicity guides prevention and management. The following classification summarises the principal mechanisms:

Mechanism	Site	Example Drugs	Pathology
Haemodynamic	Afferent arteriole	NSAIDs, COX-2 inhibitors	↓ Prostaglandin → vasoconstriction → pre-renal AKI
Haemodynamic	Efferent arteriole	ACE inhibitors, ARBs	↓ Angiotensin II → efferent dilation → ↓ GFR
Direct tubular toxicity	Proximal tubule	Aminoglycosides, cisplatin, tenofovir, ifosfamide	Tubular cell necrosis/apoptosis → ATN
Crystal nephropathy	Tubular lumen / collecting duct	Aciclovir, methotrexate, sulfonamides, indinavir	Intratubular crystal precipitation → obstruction
Immune-mediated (AIN)	Tubulointerstitium	PPIs, NSAIDs, penicillins, rifampicin	T-cell mediated interstitial inflammation → AIN
Thrombotic microangiopathy	Glomerular / arteriolar endothelium	Gemcitabine, VEGF inhibitors, calcineurin inhibitors	Endothelial injury → TMA → haemolytic uraemic syndrome
Osmotic nephrosis	Proximal tubule	IV immunoglobulin (sucrose), hydroxyethyl starch, mannitol	Vacuolisation of tubular cells → reduced GFR
Chronic tubulointerstitial	Collecting duct / interstitium	Lithium, calcineurin inhibitors (cyclosporin, tacrolimus)	Fibrosis, tubular atrophy → progressive CKD

Investigations

When drug-induced nephrotoxicity is suspected, the following investigations should be performed:

Essential

Serum creatinine & eGFR (CKD-EPI 2021)

MBS Item 66500 (renal function). Compare with baseline. A rise ≥26.5 μmol/L (0.3 mg/dL) within 48 hours or ≥50% within 7 days defines AKI (KDIGO criteria).

Essential

Serum urea & electrolytes

MBS Item 66500. Hyperkalaemia, metabolic acidosis, hyperphosphataemia indicate AKI severity.

Essential

Urinalysis & urine microscopy

MBS Item 69300. Granular casts (ATN), white cell casts (AIN), eosinophiluria (AIN — low sensitivity), crystals (crystal nephropathy).

Available

Urine sodium & fractional excretion of sodium (FENa)

FENa <1% suggests pre-renal AKI (NSAID/haemodynamic). FENa >2% suggests intrinsic ATN (aminoglycoside/cisplatin).

Available

Urinary NGAL, KIM-1 (biomarkers)

Research and selected tertiary centre use; not routinely MBS-funded. May help differentiate pre-renal from intrinsic AKI earlier than creatinine.

Available

Drug levels (lithium, gentamicin, vancomycin)

Therapeutic drug monitoring essential for dose adjustment and toxicity confirmation. Gentamicin trough (MBS via hospital lab); lithium level (MBS Item 66692).

Specialist

Renal biopsy

Indicated when drug-induced AIN is suspected but drug cannot be ceased (e.g., essential immunosuppression), or when diagnosis is uncertain and histology will change management.

Available

Renal ultrasound

MBS Item 55021. Assess kidney size, exclude obstruction, assess cortical echogenicity (↑ in CKD). Not specific for drug nephrotoxicity but essential to exclude obstructive uropathy.

Special Populations

🤰

Pregnancy

NSAIDs: Avoid in third trimester (premature ductus arteriosus closure, oligohydramnios). Short-course ibuprofen may be used in second trimester under specialist guidance.

Aminoglycosides: Category D (ototoxicity risk to foetus). Use only if no safer alternative; limit duration.

Lithium: Category D (Ebstein's anomaly risk ~0.1%). Continue only if essential; requires multidisciplinary risk-benefit assessment.

eGFR is unreliable in pregnancy — use 24-hour urine creatinine clearance for drug dosing.

👶

Paediatrics

Aminoglycosides: Gentamicin 5–7 mg/kg IV OD in children; Schwartz formula or bedside CKiD formula for GFR estimation.

NSAIDs: Ibuprofen 5–10 mg/kg PO TDS (max 40 mg/kg/day); avoid in neonates and infants <6 months (immature renal function).

Cisplatin: Paediatric oncology protocols require mandatory pre-hydration; carboplatin preferred if pre-existing renal anomaly.

Lithium: Rarely used in paediatrics; no established paediatric renal dosing guidelines in Australia.

👴

Elderly (≥65 years)

Age-related GFR decline (≈1 mL/min/year after age 40); eGFR may overestimate function in sarcopenic elderly — consider cystatin C if available.

NSAIDs: Avoid where possible; highest risk population for "triple whammy" AKI.

Aminoglycosides: Increased nephrotoxicity risk; extended-interval dosing with careful monitoring.

Lithium: Increased sensitivity to toxicity; narrow therapeutic window; dehydrated elderly at high risk of supratherapeutic levels.

🫘

Pre-existing CKD

All nephrotoxins carry amplified risk — reduced renal reserve means smaller insults cause AKI.

Check AMH / renal drug database for every new prescription.

Consider renal pharmacist review for patients with eGFR <30 or polypharmacy ≥5 medications.

🫁

Hepatic Impairment

Hepatorenal syndrome risk amplified by NSAIDs (prostaglandin inhibition).

NSAIDs absolutely contraindicated in cirrhosis with ascites.

Lithium: Altered pharmacokinetics; hypoalbuminaemia does not affect free lithium levels (not protein-bound) but dehydration is common in cirrhosis.

🛡️

Immunocompromised

Calcineurin inhibitors (cyclosporin, tacrolimus): Chronic nephrotoxicity via arteriolar hyalinosis and interstitial fibrosis — monitor drug levels and eGFR closely.

Aciclovir/valaciclovir: Crystal nephropathy risk; ensure adequate hydration; dose adjust for eGFR.

Tenofovir disoproxil (TDF): Proximal tubular toxicity (Fanconi syndrome); switch to tenofovir alafenamide (TAF) if eGFR declining.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander peoples experience CKD at 2–3 times the rate of non-Indigenous Australians, with end-stage kidney disease (ESKD) rates 7–8 times higher in some age groups (AIHW, 2023). Drug-induced nephrotoxicity is a particularly important consideration given the higher prevalence of risk factors including diabetes, hypertension, obesity, and recurrent infections requiring antibiotics.

Higher CKD prevalence

CKD prevalence in Aboriginal and Torres Strait Islander adults is approximately 22% compared with 10% in non-Indigenous Australians. This means a larger proportion of patients require renal drug dose adjustment.

Remote & rural access

Many Aboriginal and Torres Strait Islander peoples live in remote areas where specialist nephrology services are limited. Telehealth renal reviews (MBS Items 91822, 91823) are essential. Drug level monitoring (e.g., gentamicin, lithium) may require specimen transport to regional laboratories with delays.

Antibiotic prescribing

Rheumatic heart disease (RHD) prophylaxis with benzathine penicillin G (BPG) is common. Acute infections in remote communities may require aminoglycosides (gentamicin) when oral step-down options are limited. Nephrotoxic courses must be minimised and trough levels monitored where feasible.

Cultural safety

Engage Aboriginal Health Workers (AHWs) and Aboriginal Liaison Officers (ALOs) in medication counselling. Use plain language and culturally appropriate educational materials. Acknowledge kinship and community decision-making in complex prescribing decisions (e.g., continuation of lithium).

Medication adherence

Address social determinants — housing instability, food insecurity, transport barriers — that affect medication access and adherence. Consider Webster-pak dosette boxes and community pharmacy blister packing. PBS co-payment may be a barrier; ensure patients are accessing Closing the Gap PBS co-payment measure if eligible.

eGFR interpretation

The CKD-EPI 2021 equation (without race coefficient) should be used for all Australians, including Aboriginal and Torres Strait Islander peoples. There is no separate "race adjustment" in Australian practice. Be aware that some patients may have reduced muscle mass, which can overestimate eGFR.

Monitoring Framework

A structured monitoring approach minimises the risk of unrecognised drug nephrotoxicity:

Before initiation

Baseline serum creatinine, eGFR, electrolytes (K⁺), urinalysis. Document baseline renal function for all new nephrotoxic prescriptions.

1–2 weeks

Recheck creatinine and K⁺ after starting NSAIDs, ACEi/ARBs, or aminoglycosides. Earlier if risk factors present.

48–72 hours

Aminoglycoside trough level. Creatinine daily during inpatient courses.

Monthly

If on ongoing nephrotoxic therapy (e.g., chronic NSAID, calcineurin inhibitor). eGFR and electrolytes.

Every 3–6 months

Lithium levels, eGFR, electrolytes, calcium/PTH, TSH for stable lithium therapy.

At each cisplatin cycle

Pre-dose creatinine, eGFR, magnesium, potassium, phosphate. Hold cisplatin if creatinine rises >25%.

📚 References

1. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117–S314.
2. Australian Institute of Health and Welfare (AIHW). Chronic kidney disease: Australian facts. Cat. no. CKD 8. Canberra: AIHW; 2023.
3. NPS MedicineWise. The triple whammy: avoiding a dangerous combination. NPS Radar. 2022. Available from: https://www.nps.org.au
4. Australian Commission on Safety and Quality in Health Care (ACSQHC). Acute Kidney Injury Clinical Care Standard. Sydney: ACSQHC; 2020.
5. Rossi S, editor. Australian Medicines Handbook (AMH). Adelaide: AMH Pty Ltd; 2024.
6. Perazella MA. Pharmacology behind Common Drug-Nephrotoxicity Mechanisms. Clin J Am Soc Nephrol. 2023;18(10):1310–1321.
7. Lameire NH, Bagga A, Cruz D, et al. Acute kidney injury: an increasing global concern. Lancet. 2013;382(9887):170–179.
8. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2022 Update. Am J Kidney Dis. 2022;80(2):S1–S127.
9. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice (Red Book). 10th ed. East Melbourne: RACGP; 2023.
10. Haase M, Bellomo R, Devarajan P, et al. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009;54(6):1012–1024.
11. Prescribing Competencies Framework Working Group. Prescribing Competencies Framework. 2nd ed. Melbourne: NPS MedicineWise; 2021.
12. McDonald SP, Russ GR. Burden of end-stage renal disease among indigenous peoples in Australia and New Zealand. Kidney Int Suppl. 2003;(83):S123–S127.
13. RHDAustralia (Australian Government Department of Health). The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
14. Grünfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol. 2009;5(5):270–276.
15. Kidney Health Australia. Caring for Australasians with Renal Impairment (CARING) — Drug Dosing in Kidney Disease. Available from: https://www.kidney.org.au